by Lupus is a chronic autoimmune disease that causes inflammation and tissue damage in various parts of the body including joints, skin blood cells, kidneys and brain. Lupus Therapeutics including corticosteroids, antimalarials, immunosuppressants and biologics are used to control symptoms and slow the progression of the disease. These drugs help reduce inflammation, minimize immune system overactivity and manage pain and organ damage caused by lupus. Corticosteroids such as prednisone are commonly used as they help relieve joint pain, skin rashes and reduce damage to internal organs. Antimalarials such as hydroxychloroquine are also frequently used for treatment as they stabilize the autoimmune response and prevent disease flare-ups. Furthermore, immunosuppressive therapies that help regulate the immune system are beneficial for more severe lupus cases.
The global Lupus Therapeutic Market is estimated to be valued at US$ 3,035.59 million in 2023 and is expected to exhibit a CAGR of 5.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The increasing research and development of novel therapies is one of the key trends in the lupus therapeutic market. Many biopharmaceutical companies are conducting clinical trials to develop new therapeutics and treatment approaches, such as biological therapies, that can better target the underlying autoimmune mechanisms of lupus. For instance, Anthropic is working on an AI drug discovery program focused on lupus. Additionally, companies are developing therapies such as belimumab (Benlysta), anifrolumab, and sparsentan that help restore immune tolerance and curb autoimmune responses in lupus patients. The growing pipeline of innovative drugs augurs well for improved lupus management and better outcomes over the forecast period.
Porter’s Analysis
Threat of new entrants: The threat of new entrants is moderate as the development of drugs requires significant investment in R&D and clinical trials. However, smaller biotech companies can enter the market by developing novel drugs for niche patient segments.
Bargaining power of buyers: The bargaining power of buyers is high due to the presence of a large number of established players offering alternative treatment options. Buyers can negotiate on price points based on drug efficacy.
Bargaining power of suppliers: The bargaining power of suppliers is moderate as raw material inputs are commoditized and key suppliers lack differentiation. However, suppliers hold some bargaining power due to supplier concentration in niche segments.
Threat of new substitutes: The threat of new substitutes is high with continuous pipeline drugs entering trials and new treatment approaches in lupus being researched.
Competitive rivalry: The competitive rivalry is high owing to the presence of many global and regional players competing to develop novel drug molecules and target niche patient segments.
Key Takeaways
Global Lupus Therapeutic Market Demand is expected to witness high growth over the forecast period. The global Lupus Therapeutic Market is estimated to be valued at US$ 3,035.59 million in 2023 and is expected to exhibit a CAGR of 5.6% over the forecast period 2023 to 2030.
North America currently dominates the market and is expected to maintain its lead position during this period owing to growing research and development initiatives and increasing prevalence of lupus in the region. This is attributed to growing prevalence of the disease coupled with advanced healthcare infrastructure and increasing FDA approvals of novel drugs in the region. According to the Lupus Foundation of America, about 1.5 million Americans suffer from some form of lupus. Europe is also a major market owing to rising government funding for research and awareness programs related to autoimmune disorders. However, Asia Pacific is expected to witness highest growth owing to growing medical tourism, increasing disposable incomes, and expanding healthcare facilities in many countries.
The key players operating in the lupus therapeutic market are GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Pfizer, Inc., AstraZeneca, Bristol-Myers Squibb Company, Anthera Pharmaceuticals, Inc., ImmuPharma PLC. Key players are focusing on obtaining regulatory approvals and commercializing pipeline drugs to strengthen their market position. They are also exploring partnerships and collaborations to co-develop novel drugs and biologics for more effective treatment of lupus.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
